Background: Preclinical studies of liposomal doxorubicin (CAELYX™) have demonstrated significant inhibition of growth of human pancreatic cancer explains in nude mice. This study evaluated the efficacy of CAELYX™ in chemotherapy-naive patients with unresectable, histologically confirmed pancreatic carcinoma. Secondary endpoints were quality of life (QOL), time to progression and overall survival.
Introduction
Pancreatic carcinoma is the sixth commonest cause of cancer death in the developed world and the ninth worldwide [1] . The one-year survival is l%-3%. Published randomised trials suggest a median survival, in untreated populations, of two to four months [2] . Surgery is the only curative treatment. The majority of patients are diagnosed with unresectable disease. No known agents have been shown to have reproducible response rates > 15%. Until recently it was generally accepted that there was no effective chemotherapy. In phase III trials gemcitabine was found to have a statistically significant advantage in terms of both clinical benefit and one-year survival [3] .
Liposomal doxorubicin (CAELYX™, Doxil, Schering Plough) is a polyethylene glycol coated form of the anthracycline doxorubicin. The liposomal coating confers a prolonged serum half-life and gives the compound selectivity to abnormal vascular areas. The cardiotoxicity and alopecia associated with the parent compound do not occur. Preclinical studies of human pancreatic carcinoma As PC-1 subcutaneous explains in nude mice showed that 30% of mice in the CAELYX™ group were tumour free at 90 days (study end) as compared to 0%) in the adriamycin and saline groups [4] .
CAELYX™ has demonstrated activity in a number of solid malignancies including ovarian cancer; breast cancer and AIDS related Kaposi's sarcoma [5] . The toxicity profile shows that CAELYX 1 M is well tolerated and is suitable for elderly patients or patients with a reduced performance status.
Patients and methods
This study was a single centre, investigator led, single arm trial conducted at Guy's Hospital. The Guy's Hospital Ethics Committee approved the study.
Patients eligibility
Chemonaive patients with histologically proven, unresectable pancreatic carcinoma with bidimensional disease were eligible. Standard age. performance status, life expectancy, haematological and biochemical eligibility criteria were used. Left ventricular ejection fraction as determined by echocardiogram or gated nucleide heart scan had to be S: 50%. Patients may have had previous radiotherapy, but not to the sites of measurable disease. In the four weeks before starting chemotherapy, patients were staged by physical examination, chest X-ray and computed tomography (CT) scan. All patients gave informed consent.
Treatment plan

CAELYX
IM was given as a one-hour infusion. In line with available phase I data, the first five patients were given a starting dose of 30 mg/m 2 three-weekly. This was tolerated without toxicity Subsequent patients received 50 mg/m 2 four-weekly following the finding that the MTD in ongoing phase I trials was 60 mg/m 2 four-weekly [6] or 50 mg/m 2 three-weekly [7] . These trials also found a significant reduction in efficacy on reducing the dose of CAELYX™. The reduction in response rate in solid tumours was from 50% at 60 mg/m 2 to 30% at 45 mg/m" and 0% at 20 mg/m* [8]. The dosing interval was increased to four-weekly as the nadir for CAELYX rM was found to be 21 days. The increased interval would also allow CAELYX™ to be cleared from the skin minimising the development of palmar-plantar erythrodysaelhesia (PPE) from cumulative dosing.
Assessment of efficacy
Response was evaluated with CT scanning, using standard World Health Organisation criteria, every two cycles of chemotherapy. Toxicity was assessed before every cycle of chemotherapy using the CALGB expanded common toxicity criteria. Haematology was performed weekly. The EORTC QLQ-C30 2.0.
[9] and standardised visual analogue score for pain and analgesic consumption were administered before each cycle of chemotherapy.
Statistical analysis
The study employed a two stage Simon's design with P o = 0.1. P, = 0.3. a = 0.1 and |3 = 0.1 to optimise the probability of detecting a real response and minimise further investigation of an ineffective agent Survival and time to progression were calculated using the KaplanMeier method and measured from date of first chemotherapy.
Results
From 9 January 1998 to 30 September 1999, 22 patients (9 males and 13 females) were entered. The median age was 65 (range 49 to 79) years with ECOG performance status of 0 (2 patients), 1 (14 patients) and 2 (6 patients). Six patients had locally advanced disease and 14 metastatic disease. Four had undergone prior surgery and six pretreatment biliary stenting. Two patients who died, after giving consent, but before starting chemotherapy, are not included in the analysis. Fifty-one cycles of chemotherapy were given. Twenty patients received at least one cycle with a median of two cycles (range one to six). All 20 patients were evaluable for toxicity and 16 were evaluable for response. Four patients were not evaluable for response: three died of their disease before their first reassessment and one patient withdrew from the study after one cycle due to toxicity. Five patients received second line therapy after completing the study. Four received flutamide and one received gemcitabine.
Response
No complete or partial responses were observed. Six patients had stable disease after two cycles of therapy and three after six (Table 2) . Ten patients had progressive disease.
Survival
Median survival was 3.2 months (range 21 days to 19.4 months). For patients with stable disease as best response median time to progression was 4.2 months (range 2.1 to 19.4 months) and median survival 7.1 months (range 2.1 to 19.4 months). Two patients (10%) were alive at one year.
Toxicity
CAELYX™ was well tolerated. One patient suffered a grade 4 toxicity, PPE, and required a dose reduction and delay. Six patients experienced a grade 3 toxicity: two had nausea; four stomatitis (one of whom had a blocked biliary stent). There were no treatment-related deaths. One more patient required treatment delay due to a deep vein thrombosis.
Quality of life
Eight patients completed more than one EORTC QLQ-C30 questionnaire: two completed five, two completed three and four completed two. When the baseline questionnaire was compared with the second questionnaire and the last available questionnaire there was no significant change in global QOL or in any functional or symptom subscale scores.
When baseline weight and performance status were compared with weight and performance status after two cycles and final weight and performance status, no significant differences were found. When these analyses were applied to subgroups of patients with stable disease and progressive disease respectively, no significant difference was found. With so few patients, confidence limits were wide and significant differences could not be excluded.
Incomplete data for pain and analgesic consumption made analysis impossible.
Discussion
In this study, no complete or partial responses were seen. Six patients had stable disease. The one-year survival was 10%.
A recently reported phase II study of Caelyx in platinum and paclitaxel refractory ovarian cancer suggests that the effect of CAELYX™ is delayed. The median time to response was 15.4 weeks. The average patient would have required four cycles of chemotherapy monthly to detect a radiological response [10] . CAELYX™ may maintain response and improve oneyear survival when used in combination with a more rapidly acting drug which increases the number of patients surviving long enough to benefit from the effects of CAELYX™.
There was insufficient data in this trial to comment on the effects of CAELYX™ on quality of life. This was due to small patient numbers and poor compliance in completing questionnaires. Poor compliance was due to patients being too unwell, or refusing to complete questionnaires, or to clerical oversight. This was despite adherence to Medical Research Council recommendations for incorporation of QOL measurements in clinical trial protocols [II] . CAELYX™ was well tolerated in this study with only one grade 4 toxicity (PPE). There was a low incidence of nausea, vomiting and haematological toxicity and no total alopecia. CAELYX 1 M is easy to administer (A single, outpatient, one-hour injection four-weekly) making it an ideal drug for a group of patients that tend to be frail and elderly.
CAELYX™ has a favourable toxicity profile and produces stable disease responses in advanced pancreatic carcinoma. It warrants further consideration in the context of combination trials with clinical benefit endpoints [12] .
